Related Experiment Video
Updated: Mar 11, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Initial Response to Transcranial Magnetic Stimulation Treatment for Depression Predicts Subsequent Response
Michael S Kelly1, Albino J Oliveira-Maia1, Margo Bernstein1
1From the Berenson-Allen Center for Noninvasive Brain Stimulation, Division of Cognitive Neurology, Department of Neurology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston (MSK, AJO-M, MB, APS, DZP, AP-L, ADB); the University of Rochester School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, N.Y. (MSK); the Champalimaud Research and Clinical Centre, Champalimaud Centre for the Unknown, Lisboa, Portugal (AJO-M); the Department of Psychiatry and Mental Health, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal (AJO-M); NOVA Medical School|Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal (AJO-M); the Department of Psychiatry at BIDMC (APS); and the Noninvasive Brain Stimulation Clinical Program, Departments of Pediatrics and Neurology, University of Iowa Hospitals and Clinics, Iowa City, Iowa (ADB).
Abstract:
This study provides support for the hypothesis that treatment response to an initial course of repetitive transcranial magnetic stimulation (rTMS) for depression predicts the magnitude of response to a subsequent course of rTMS in the setting of symptom relapse.

